CTA056
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406282
CAS#:1265822-30-7
Description:CTA056 is a potent and selective ITK inhibitor (interleukin-2-inducible T-cell kinase inhibitor). ITK is a member of the Btk (Bruton's tyrosine kinase) family of tyrosine kinases, plays an important role in normal T-cell functions and in the pathophysiology of both autoimmune diseases and T-cell malignancies. CTA056 exhibits the highest inhibitory effects toward Itk, followed by Btk and endothelial and epithelial tyrosine kinase. Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. CTA056 may be potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.
Price and Availability
CTA056 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, SDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 406282Name: CTA056CAS#: 1265822-30-7Chemical Formula: C35H34N6OExact Mass: 554.27941Molecular Weight: 554.68Elemental Analysis: C, 75.79; H, 6.18; N, 15.15; O, 2.88
Synonym:CTA056; CTA-056; CTA 056
IUPAC/Chemical Name:7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin-4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one
InChi Key:BSSBAJKNZOHHCA-UHFFFAOYSA-N
InChi Code:InChI=1S/C35H34N6O/c42-35-32(22-25-8-3-1-4-9-25)37-30-24-33-31(23-29(30)39-35)38-34(41(33)21-7-20-40-18-5-2-6-19-40)28-12-10-26(11-13-28)27-14-16-36-17-15-27/h1,3-4,8-17,23-24H,2,5-7,18-22H2,(H,39,42)
SMILES Code:O=C1NC2=CC3=C(N(CCCN4CCCCC4)C(C5=CC=C(C6=CC=NC=C6)C=C5)=N3)C=C2N=C1CC7=CC=CC=C7
Technical Data
Additional Information
References
1: Guo W, Liu R, Ono Y, Ma AH, Martinez A, Sanchez E,Wang Y, Huang W, Mazloom A, Li J, Ning J, Maverakis E, Lam KS, Kung HJ.Molecular characteristics of CTA056, novel interleukin-2-inducibleT-cell kinase inhibitor that selectively targets malignant Tcells and modulates oncomirs. Mol Pharmacol. 2012 Nov;82(5):938-47. doi:10.1124/mol.112.079889. Epub 2012 Aug 16. PubMed PMID: 22899868; PubMedCentral PMCID: PMC3477223.
